Aripiprazol as an adjuvant on obsessive compulsive symptoms in patients with Schizophrenia – A randomized placebo-controlled study

Mazandaran University of Medical Sciences0 个研究点目标入组 40 人开始时间: 待定最近更新: 2019年1月14日

适应症

试验速览

暂无简介。

•Women and men admitted to the psychiatric wards of the Zare hospital in Sari, who were between the ages of 18 and 65.
•Patients diagnosed with schizophrenia based on DSM-5 criteria that simultaneously had obsessive-compulsive symptoms.
•If they received medications such as mood-stabilizers and anti-depressant medications along with their antipsychotic regimen, their dosage was fixed one month before the study began and during the study.

•The presence of psychiatric disorders in the first axis, as bipolar disorder or major depressive disorder.
•Substance dependency (based on DSM-5, as well as 6-month relapse or substance abuse in the three months prior to the onset of the study or positive urine specimen testing at the start of the study).
•Patients treated with ECT in the last six months.
•Individuals with suicidal/homicidal ideas or attempts at the start of the study or 6 months before the start of the study.
•People with intellectual disabilities.
•Pregnant or lactating women.
•Patients with neurological disorders such as dementia, delirium, uncontrolled seizure and head trauma.
•People with uncontrolled underlying conditions such as cardiovascular disease, liver and kidney failure, various malignancies, endocrine disorders and hematological disorders.
•Patients who have already been treated with aripiprazole.
•Patients who had a history of allergy or intolerance to aripiprazole.

发起方